Moderate-risk patients with diabetes treated with a sulfonylurea appear to be at a higher risk of major adverse cardiovascular events than those who receive a dipeptidyl peptidase-4 (DPP-4) inhibitor, ...
Odds are lessened with regular diabetes-related medical care. (HealthDay News) — The prevalence of impaired awareness of hypoglycemia (IAH) is high among patients using sulfonylureas long term, ...
Type 2 diabetes medications, such as sulfonylureas, have been a mainstay of treating the disease since they came on the market in the early 1950s. However, although they are one of the most common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results